Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 0 · FY2024 0
Georgian pharmaceutical wholesale/distribution company. Limited public information available beyond the Reportal filing.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 8,940 | 13,052 | 21,803 | 42,707 | 31,448 | 28,913 | 53,482 | +34.7% | |
| 15 | 5,930 | 6,473 | 10,067 | 18,309 | 38,545 | 36,883 | nmf | |
| TOTAL ASSETS | 8,955 | 18,981 | 28,276 | 52,774 | 49,757 | 67,458 | 90,365 | +47.0% |
| 6,179 | 14,742 | 16,250 | 31,896 | 14,590 | 15,129 | 12,852 | +13.0% | |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| TOTAL LIABILITIES | 6,179 | 14,742 | 16,250 | 31,896 | 14,590 | 15,129 | 12,852 | +13.0% |
| 2,776 | 4,239 | 12,026 | 20,878 | 35,167 | 52,329 | 77,513 | +74.2% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | ||||||||
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Equivalents | 1,140 | 1,649 | 2,518 | 24,393 | 19,587 | 5,403 | 23,869 | +66.0% |
| Net Debt | 1,140 | 1,649 | 2,518 | 24,393 | 19,587 | 5,403 | 23,869 | +66.0% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →